|Bid||21.35 x 900|
|Ask||21.39 x 800|
|Day's Range||21.03 - 21.74|
|52 Week Range||19.36 - 45.16|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.83|
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Director and CEO, Alkermes plc of Alkermes Plc (30-Year Financial, Insider Trades) Richard F Pops (insider trades) sold 100,000 shares of ALKS on 09/12/2019 at an average price of $22.68 a share. Continue reading...
DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of Directors. The company also announced the retirement of Floyd Bloom, M.D., a pioneer in the field of neuroscience who contributed immensely to the legacy of innovation and scientific excellence that remains core to Alkermes' mission today. Dr. Gaynor, who currently serves as the President of Research & Development at Neon Therapeutics, brings 18 years of experience in oncology-focused industrial drug development in addition to a distinguished career in academic medicine.
In this article we are going to estimate the intrinsic value of Alkermes plc (NASDAQ:ALKS) by taking the foreast...
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores ≥2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).
Under the agreement, the parties agreed to request termination of the IPR and Alkermes granted Amneal the non-exclusive right to market a generic formulation of VIVITROL in the U.S. beginning sometime in 2028 or earlier under certain circumstances. Additional terms of the agreement are confidential.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
-- Second Quarter Revenues of $279.9 Million , Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.27 and Non-GAAP ...
DUBLIN , July 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, July 25, 2019 , to discuss the company's ...
If you own shares in Alkermes plc (NASDAQ:ALKS) then it's worth thinking about how it contributes to the volatility of...
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.